Top

Journal of Ovarian Research

Published in:

Open Access 01-12-2014 | Research

A high M1/M2 ratio of tumor-associated macrophages is associated with extended survival in ovarian cancer patients

Authors: Meiying Zhang, Yifeng He, Xiangjun Sun, Qing Li, Wenjing Wang, Aimin Zhao, Wen Di

Published in: Journal of Ovarian Research | Issue 1/2014

Abstract

Background

Tumor-associated macrophages (TAMs) are classified into two major phenotypes, M1 and M2. M1 TAMs suppress cancer progression, while M2 TAMs promote it. However, little is known regarding the role of TAMs in the development of ovarian cancer. Here, we investigated the relationship between TAM distribution patterns (density, microlocalization, and differentiation) and ovarian cancer histotypes, and we explored whether altered TAM distribution patterns influence long-term outcomes in ovarian cancer patients.

Methods

A total of 112 ovarian cancer patients were enrolled in this study, and the subjects were divided into two groups according to their survival (< 5 years vs. ≥ 5 years). Immunohistochemistry and immunofluorescence were used to determine the density, microlocalization, and differentiation status of TAMs in ovarian cancer tissues for each histotype. Kaplan-Meier survival and multivariate Cox regression analyses were used to evaluate the prognostic significance of TAM-related parameters in ovarian cancer.

Results

TAMs most frequently infiltrated into the cancer tissue of the serous histotype, followed by mucinous, undifferentiated, endometrioid, and clear cell histotypes (p = 0.049). The islet/stroma ratio of total TAMs varied among the cancer histotypes, with mucinous and undifferentiated cancers displaying the lowest and highest ratios, respectively (p = 0.005). The intratumoral TAM density significantly increased with increasing cancer stage and grade (p = 0.023 and 0.006, respectively). However, the overall M1/M2 TAM ratio decreased as the cancer stage increased (p = 0.012). In addition, the intra-islet M1/M2 ratio inversely correlated with the residual site size (p = 0.004). Among the TAM-related parameters, only the increased overall and intra-islet M1/M2 TAM ratios displayed prognostic significance in both the Kaplan-Meier survival and multivariate Cox regression analyses; however, the values of these two parameters did not differ significantly among the cancer histotypes.

Conclusions

The patients with increased overall or intra-islet M1/M2 TAM ratios presented with an improved 5-year prognosis. Nevertheless, the TAM distribution patterns did not influence the overall outcomes of different ovarian cancer histotypes.

Available only for authorised users

Liliac L, Amalinei C, Balan R, Grigoras A, Caruntu ID: Ovarian cancer: insights into genetics and pathogeny. Histol Histopathol 2012, 27: 707–719.PubMed

Prat J: Ovarian carcinomas: five distinct diseases with different origins, genetic alterations, and clinicopathological features. Virchows Arch 2012, 460: 237–249. 10.1007/s00428-012-1203-5CrossRefPubMed

Bharwani N, Reznek RH, Rockall AG: Ovarian cancer management: the role of imaging and diagnostic challenges. Eur J Radiol 2011, 78: 41–51. 10.1016/j.ejrad.2010.11.039CrossRefPubMed

Salani R, Bristow RE: Surgical management of epithelial ovarian cancer. Clin Obstet Gynecol 2012, 55: 75–95. 10.1097/GRF.0b013e31824b4629CrossRefPubMed

Ross JA, Auger MJ: The Biology of the Macrophage. In Origins of the Macrophage. 2nd edition. Edited by: Burke B, Lewis CE. Oxford (United Kingdom): Oxford University Press; 2002.

Gonzalez-Mejia ME, Doseff AI: Regulation of monocytes and macrophages cell fate. Front Biosci (Landmark Ed) 2009, 14: 2413–2431.CrossRef

Opdenakker G, Van Damme J: Cytokines and proteases in invasive processes: molecular similarities between inflammation and cancer. Cytokine 1992, 4: 251–258. 10.1016/1043-4666(92)90064-XCrossRefPubMed

Staudt ND, Jo M, Hu J, Bristow JM, Pizzo DP, Gaultier A, VandenBerg SR, Gonias SL: Myeloid cell receptor LRP1/CD91 regulates monocyte recruitment and angiogenesis in tumors. Cancer Res 2013, 73: 3902–3912. 10.1158/0008-5472.CAN-12-4233PubMedCentralCrossRefPubMed

Mukherji B: In vitro assay of spontaneous cytotoxicity by human monocytes and macrophages against tumor cells. J Immunol Methods 1980, 37: 233–247. 10.1016/0022-1759(80)90310-5CrossRefPubMed

10.

Tokunaga N, Murakami T, Endo Y, Nishizaki M, Kagawa S, Tanaka N, Fujiwara T: Human monocyte-derived dendritic cells pulsed with wild-type p53 protein efficiently induce CTLs against p53 overexpressing human cancer cells. Clin Cancer Res 2005, 11: 1312–1318.PubMed

11.

Thomas C, Fertil B: Sensitivity of human melanoma cells to adherent leukocytes depends on the ratio between them, the activation status of adherent leukocytes and the metastatic potential of tumor cells. Cancer Immunol Immunother 2001, 50: 181–190. 10.1007/s002620100186CrossRefPubMed

12.

Lewis CE, Pollard JW: Distinct role of macrophages in different tumor microenvironments. Cancer Res 2006, 66: 605–612. 10.1158/0008-5472.CAN-05-4005CrossRefPubMed

13.

Kosaka T, Kuwabara M, Endo A, Tamaguchi H, Koide F: Expression of arginase by mouse myeloid leukemic cell differentiation in vitro induced with tumor necrosis factor. J Vet Med Sci 1991, 53: 53–57. 10.1292/jvms.53.53CrossRefPubMed

14.

Mantovani A, Sica A, Allavena P, Garlanda C, Locati M: Tumor-associated macrophages and the related myeloid-derived suppressor cells as a paradigm of the diversity of macrophage activation. Hum Immunol 2009, 70: 325–330. 10.1016/j.humimm.2009.02.008CrossRefPubMed

15.

Mills CD, Kincaid K, Alt JM, Heilman MJ, Hill AM: M-1/M-2 macrophages and the Th1/Th2 paradigm. J Immunol 2000, 164: 6166–6173.CrossRefPubMed

16.

Leek RD, Hunt NC, Landers RJ, Lewis CE, Royds JA, Harris AL: Macrophage infiltration is associated with VEGF and EGFR expression in breast cancer. J Pathol 2000, 190: 430–436. 10.1002/(SICI)1096-9896(200003)190:4<430::AID-PATH538>3.0.CO;2-6CrossRefPubMed

17.

Zhang J, Lu Y, Pienta KJ: Multiple roles of chemokine(C-C motif) ligand 2 in promoting prostate cancer growth. J Natl Cancer Inst 2010, 102: 522–528. 10.1093/jnci/djq044PubMedCentralCrossRefPubMed

18.

Shen Z, Seppainen H, Vainionpaa S, Ye Y, Wang S: IL10, IL11, IL18 are differently expressed in CD14+ TAMs and play different role in regulating the invasion of gastric cancer cells under hypoxia. Cytokine 2012, 59: 352–357. 10.1016/j.cyto.2012.04.033CrossRefPubMed

19.

Kong LY, Wu AS, Doucette T, Wei J, Priebe W, Fuller GN, Qiao W, Sawaya R, Rao G, Heimberger AB: Intratumoral mediated immunosuppression is prognostic in genetically engineered murine models of glioma and correlates to immunotherapeutic responses. Clin Cancer Res 2010, 16: 5722–5733. 10.1158/1078-0432.CCR-10-1693PubMedCentralCrossRefPubMed

20.

Mantovani A, Sozzani S, Locati M, Allavena P, Sica A: Macrophage polarization:tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol 2002, 23: 549–555. 10.1016/S1471-4906(02)02302-5CrossRefPubMed

21.

Lim D, Oliva E: Precursors and pathogenesis of ovarian carcinoma. Pathology 2013, 45: 229–242. 10.1097/PAT.0b013e32835f2264CrossRefPubMed

22.

McCluggage WG: Morphological subtypes of ovarian carcinoma: a review with emphasis on new developments and pathogenesis. Pathology 2011, 43: 420–432. 10.1097/PAT.0b013e328348a6e7CrossRefPubMed

23.

Kurman RJ, Shih IM: Molecular pathogenesis and extraovarian origin of epithelial ovarian cancer–shifting the paradigm. Hum Pathol 2011, 42: 918–931. 10.1016/j.humpath.2011.03.003PubMedCentralCrossRefPubMed

24.

Kurman RJ, Shih IM: The origin and pathogenesis of epithelial ovarian cancer: a proposed unifying theory. Am J Surg Pathol 2010, 34: 433–443. 10.1097/PAS.0b013e3181cf3d79PubMedCentralCrossRefPubMed

25.

Wong KH, Mang OW, Au KH, Law SC: Incidence, mortality, and survival trends of ovarian cancer in Hong Kong, 1997 to 2006: a population-based study. Hong Kong Med J 2012, 18: 466–474.PubMed

26.

Schiff M, Becker TM, Smith HO, Gilliland FD, Key CR: Ovarian cancer incidence and mortality in American Indian, Hispanic, and non-Hispanic white women in New Mexico. Cancer Epidemiol Biomarkers Prev 1996, 5: 323–327.PubMed

27.

Flesken-Nikitin A, Hwang CI, Cheng CY, Michurina TV, Enikolopov G, Nikitin AY: Ovarian surface epithelium at the junction area contains a cancer-prone stem cell niche. Nature 2013, 495: 241–245. 10.1038/nature11979PubMedCentralCrossRefPubMed

28.

Tafe LJ, Garg K, Chew I, Tornos C, Soslow RA: Endometrial and ovarian carcinomas with undifferentiated components: clinically aggressive and frequently underrecognized neoplasms. Mod Pathol 2010, 23: 781–789. 10.1038/modpathol.2010.41CrossRefPubMed

29.

Edin S, Wikberg ML, Dahlin AM, Rutegard J, Oberg A, Oldenborg PA, Palmgvist R: The distribution of macrophages with a M1 or M2 phenotype in relation to prognosis and the molecular characteristics of colorectal cancer. PloS One 2012, 7: e47045. 10.1371/journal.pone.0047045PubMedCentralCrossRefPubMed

30.

Ohri CM, Shikotra A, Green RH, Waller DA, Bradding P: Macrophages within NSCLC tumour islets are predominantly of a cytotoxic M1 phenotype associated with extended survival. Eur Respir J 2009, 33: 118–126. 10.1183/09031936.00065708CrossRefPubMed

31.

Waldemarson S, Krogh M, Alaiya A, Kirik U, Schedvins K, Auer G, Hansson KM, Ossola R, Lee H, Malmstrom J, James P: Protein expression changes in ovarian cancer during the transition from benign to malignant. J Proteome Res 2012, 11: 2876–2889. 10.1021/pr201258qCrossRefPubMed

32.

Zhu Y, Wu R, Sangha N, Yoo C, Cho KR, Shedden KA, Katabuchi H, Lubman DM: Classifications of ovarian cancer tissues by proteomic patterns. Proteomics 2006, 6: 5846–5856. 10.1002/pmic.200600165CrossRefPubMed

33.

Denny L, Hacker NF, Gori J: Staging Classifications and Clinical Practice Guidelines for Gynaecological Cancers. 3rd edition. London: Elsevier; 2006.

34.

Stany MP, Vathipadiekal V, Ozbun L, Stone RL, Mok SC, Xue H, Kagami T, Wang Y, McAlpine JN, Bowtell D, Gout PW, Miller DM, Gilks CB: Identification of novel therapeutic targets in microdissected clear cell ovarian cancers. PloS One 2011, 6: e21121. 10.1371/journal.pone.0021121PubMedCentralCrossRefPubMed

35.

Medrek C, Ponten F, Jirstrom K, Leandersson K: The presence of tumor associated macrophages in tumor stroma as a prognostic marker for breast cancer patients. BMC Cancer 2012, 12: 306. 10.1186/1471-2407-12-306PubMedCentralCrossRefPubMed

36.

Dun EC, Hanley K, Wieser F, Bohman S, Yu J, Taylor RN: Infiltration of tumor-associated macrophages is increased in the epithelial and stromal compartments of endometrial carcinomas. Int J Gynecol Pathol 2013, 32: 576–584. 10.1097/PGP.0b013e318284e198CrossRefPubMed

37.

Hasita H, Komohara Y, Okabe H, Masuda T, Ohnishi K, Lei XF, Beppu T, Baba H, Takeya M: Significance of alternatively activated macrophages in patients with intrahepatic cholangiocarcinoma. Cancer Sci 2010, 101: 1913–1919. 10.1111/j.1349-7006.2010.01614.xCrossRefPubMed

38.

Kong L-Q, Zhu X-D, Xu H-X, Zhang J-B, Lu L: The clinical significance of the CD163+ and CD68+ macrophages in patients with hepatocellular Carcinoma. PloS One 2013, 8: e59771. 10.1371/journal.pone.0059771PubMedCentralCrossRefPubMed

39.

Costa NL, Valadares MC, Souza PP, Mendonça EF, Oliveira JC, Silva TA, Batista AC: Tumor-associated macrophages and the profile of inflammatory cytokines in oral squamous cell carcinoma. Oral Oncol 2013, 49: 216–223. 10.1016/j.oraloncology.2012.09.012CrossRefPubMed

40.

Partecke LI, Günther C, Hagemann S, Jacobi C, Merkel M, Sendler M, van Rooijen N, Käding A, Nguyen Trung D, Lorenz E, Diedrich S, Weiss FU, Heidecke CD, von Bernstorff W: Induction of M2-macrophages by tumour cells and tumour growth promotion by M2-macrophages: A quid pro quo in pancreatic cancer. Pancreatology 2013, 13: 508–516. 10.1016/j.pan.2013.06.010CrossRefPubMed

41.

Shigeoka M, Urakawa N, Nakamura T, Nishio M, Watajima T, Kuroda D, Komori T, Kakeji Y, Semba S, Yokozaki H: Tumor associated macrophage expressing CD204 is associated with tumor aggressiveness of esophageal squamous cell carcinoma. Cancer Sci 2013, 104: 1112–1119. 10.1111/cas.12188CrossRefPubMed

42.

Ishigami S, Natsugoe S, Tokuda K, Nakajo A, Okumura H: Tumor associated macrophage (TAM) infiltration in gastric cancer. Anticancer Res 2003, 23: 4079–4083.PubMed

43.

Qing W, Fang WY, Ye L, Shen LY, Zhang XF, Fei XC, Chen X, Wang WQ, Li XY, Xiao JC, Ning G: Density of tumor-associated macrophages correlates with lymph node metastasis in papillary thyroid carcinoma. Thyroid 2012, 22: 905–910. 10.1089/thy.2011.0452PubMedCentralCrossRefPubMed

44.

Kawanaka T, Kubo A, Ikushima H, Sano T, Takegawa Y: Prognostic significance of HIF-2alpha expression on tumor infiltrating macrophages in patients with uterine cervical cancer undergoing radiotherapy. J Med Invest 2008, 55: 78–86. 10.2152/jmi.55.78CrossRefPubMed

45.

Ajili F, Kourda N, Darouiche A, Chebil M, Boubaker S: Prognostic value of tumor-associated macrophages count in human non-muscle-invasive bladder cancer treated by BCG immunotherapy. Ultrastruct Pathol 2013, 37: 56–61. 10.3109/01913123.2012.728688CrossRefPubMed

46.

Fujii T, Shimada K, Asai O, Tanaka N, Fujimoto K, Hirao K, Konishi N: Immunohistochemical analysis of inflammatory cells in benign and precancerous lesions and carcinoma of the prostate. Pathobiology 2013, 80: 119–126. 10.1159/000342396CrossRefPubMed

47.

Zhang QW, Liu L, Gong CY, Shi HS, Zeng YH, Wang XZ, Zhao YW, Wei YQ: Prognostic significance of tumor-associated macrophages in solid tumor: a meta-analysis of the literature. PLoS One 2012, 7: e50946. 10.1371/journal.pone.0050946PubMedCentralCrossRefPubMed

48.

Dong Y, Walsh MD, Cummings MC, Wright RG, Khoo SK, Parsons PG, McGuckin MA: Expression of MUC1 and MUC2 mucins in epithelial ovarian tumours. J Pathol 1997, 183: 311–317. 10.1002/(SICI)1096-9896(199711)183:3<311::AID-PATH917>3.0.CO;2-2CrossRefPubMed

49.

Tashiro Y, Yonezawa S, Kim YS, Sato E: Immunohistochemical study of mucin carbohydrates and core proteins in human ovarian tumors. Hum Pathol 1994, 25: 364–372. 10.1016/0046-8177(94)90144-9CrossRefPubMed

50.

Inaba T, Sano H, Kawahito Y, Hla T, Akita K: Induction of cyclooxygenase-2 in monocyte/macrophage by mucins secreted from colon cancer cells. Proc Natl Acad Sci 2003, 100: 2736–2741. 10.1073/pnas.0435410100PubMedCentralCrossRefPubMed

51.

Chauhan SC, Singh AP, Ruiz F, Johansson SL, Jain M, Smith LM, Moniaux N, Batra SK: Aberrant expression of MUC4 in ovarian carcinoma: diagnostic significance alone and in combination with MUC1 and MUC16 (CA125). Mod Pathol 2006, 19: 1386–1394. 10.1038/modpathol.3800646CrossRefPubMed

52.

Tian C, Markman M, Zaino R, Ozols RF, McGuire WP, Muggia FM, Rose PG, Spriggs D, Armstrong DK: CA-125 change after chemotherapy in prediction of treatment outcome among advanced mucinous and clear cell epithelial ovarian cancers: a Gynecologic Oncology Group study. Cancer 2009, 115: 1395–1403. 10.1002/cncr.24152PubMedCentralCrossRefPubMed

53.

Singh AP, Senapati S, Ponnusamy MP, Jain M, Lele SM, Davis JS, Remmenga S, Batra SK: Clinical potential of mucins in diagnosis, prognosis, and therapy of ovarian cancer. Lancet Oncol 2008, 9: 1076–1085. 10.1016/S1470-2045(08)70277-8CrossRefPubMed

54.

Tsai-Turton M, Santillan A, Lu D, Bristow RE, Chan KC, Shih IM, Roden RB: P53 autoantibodies, cytokine levels and ovarian carcinogenesis. Gynecol Oncol 2009, 114: 12–17. 10.1016/j.ygyno.2009.03.028PubMedCentralCrossRefPubMed

55.

Allavena P, Chieppa M, Bianchi G, Solinas G, Fabbri M, Laskarin G, Mantovani A: Engagement of the mannose receptor by tumoral mucins activates an immune suppressive phenotype in human tumor-associated macrophages. Clin Dev Immunol 2010, 2010: 547179.PubMedCentralCrossRefPubMed

56.

Albarracin CT, Jafri J, Montag AG, Hart J, Kuan SF: Differential expression of MUC2 and MUC5AC mucin genes in primary ovarian and metastatic colonic carcinoma. Hum Pathol 2000, 31: 672–677. 10.1053/hupa.2000.6799CrossRefPubMed

57.

Garg K, Leitao MM Jr, Kauff ND, Hansen J, Kosarin K, Shia J, Soslow RA: Selection of endometrial carcinomas for DNA mismatch repair protein immunohistochemistry using patient age and tumor morphology enhances detection of mismatch repair abnormalities. Am J Surg Pathol 2009, 33: 925–933. 10.1097/PAS.0b013e318197a046CrossRefPubMed

58.

Kozłowska A, Mackiewicz J, Mackiewicz A: Therapeutic gene modified cell based cancer vaccines. Gene 2013, 525: 200–207. 10.1016/j.gene.2013.03.056CrossRefPubMed

59.

Hodges RR, Dartt DA: Tear film mucins: front line defenders of the ocular surface; comparison with airway and gastrointestinal tract mucins. Exp Eye Res 2013, 117: 62–78.PubMedCentralCrossRefPubMed

60.

Gubbels JA, Belisle J, Onda M, Rancourt C, Migneault M, Ho M, Bera TK, Connor J, Sathyanarayana BK, Lee B, Pastan I, Patankar MS: Mesothelin-MUC16 binding is a high affinity. N-glycan dependent interaction that facilitates peritoneal metastasis of ovarian tumors. Mol Cancer 2006, 5: 50. 10.1186/1476-4598-5-50PubMedCentralCrossRefPubMed

61.

Kawashima H: Roles of the gel-forming MUC2 mucin and its O-glycosylation in the protection against colitis and colorectal cancer. Biol Pharm Bull 2012, 35: 1637–1641. 10.1248/bpb.b12-00412CrossRefPubMed

62.

Bäckström M, Ambort D, Thomsson E, Johansson ME, Hansson GC: Increased understanding of the biochemistry and biosynthesis of MUC2 and other gel-forming mucins through the recombinant expression of their protein domains. Mol Biotechnol 2013, 54: 250–256. 10.1007/s12033-012-9562-3CrossRefPubMed

63.

Perez-Vilar J, Mabolo R: Gel-forming mucins. Notions from in vitro studies. Histol Histopathol 2007, 22: 455–464.PubMed

64.

Komohara Y, Horlad H, Ohnishi K, Fujiwara Y, Bai B, Nakagawa T, Suzu S, Nakamura H, Kuratsu J, Takeya M: Importance of direct macrophage-tumor cell interaction on progression of human glioma. Cancer Sci 2012, 103: 2165–2172. 10.1111/cas.12015CrossRefPubMed

65.

Kostova N, Zlateva S, Ugrinova I, Pasheva E: The expression of HMGB1 protein and its receptor RAGE in human malignant tumors. Mol Cell Biochem 2010, 337: 251–258. 10.1007/s11010-009-0305-0CrossRefPubMed

66.

Vaksman O, Davidson B, Tropé C, Reich R: Calreticulin expression is reduced in high-grade ovarian serous carcinoma effusions compared with primary tumors and solid metastases. Hum Pathol 2013, 44: 2677–2683. 10.1016/j.humpath.2013.07.009CrossRefPubMed

67.

Kepp O, Tesniere A, Zitvogel L, Kroemer G: The immunogenicity of tumor cell death. Curr Opin Oncol 2009, 21: 71–76. 10.1097/CCO.0b013e32831bc375CrossRefPubMed

68.

Melichar B, Savary CA, Patenia R, Templin S, Melicharova K, Freedman RS: Phenotype and antitumor activity of ascitic fluid monocytes in patients with ovarian carcinoma. Int J Gynecol Cancer 2003, 13: 435–443. 10.1046/j.1525-1438.2003.13331.xCrossRefPubMed

69.

Jeon BH, Jang C, Han J, Kataru RP, Piao L, Jung K, Cha HJ, Schwendener RA, Jang KY, Kim KS, Alitalo K, Koh GY: Profound but dysfunctional lymphangiogenesis via vascular endothelial growth factor ligands from CD11b + macrophages in advanced ovarian cancer. Cancer Res 2008, 68: 1100–1109. 10.1158/0008-5472.CAN-07-2572CrossRefPubMed

70.

Wilson AJ, Barham W, Saskowski J, Tikhomirov O, Chen L, Lee HJ, Yull F, Khabele D: Tracking NF-kappaB activity in tumor cells during ovarian cancer progression in a syngeneic mouse model. J Ovarian Res 2013, 6: 63. 10.1186/1757-2215-6-63PubMedCentralCrossRefPubMed

71.

Zaki MA, Wada N, Ikeda J, Shibayama H, Hashimoto K, Yamagami T, Tatsumi Y, Tsukaguchi M, Take H, Tsudo M, Morii E, Aozasa K: Prognostic implication of types of tumor-associated macrophages in Hodgkin lymphoma. Virchows Arch 2011, 459: 361–366. 10.1007/s00428-011-1140-8CrossRefPubMed

72.

Hanada T, Nakagawa M, Emoto A, Nomura T, Nasu N, Nomura Y: Prognostic value of tumor-associated macrophage count in human bladder cancer. Int J Urol 2000, 7: 263–269. 10.1046/j.1442-2042.2000.00190.xCrossRefPubMed

73.

Lissbrant IF, Stattin P, Wikstrom P, Damber JE, Egevad L, Bergh A: Tumor associated macrophages in human prostate cancer: relation to clinicopathological variables and survival. Int J Oncol 2000, 17: 445–451.PubMed

74.

Lin EY, Nguyen AV, Russell RG, Pollard JW: Colony stimulating factor 1 promotes progression of mammary tumors to malignancy. J Exp Med 2001, 193: 727–740. 10.1084/jem.193.6.727PubMedCentralCrossRefPubMed

75.

Aharinejad S, Paulus P, Sioud M, Hofmann M, Zins K, Schäfer R, Stanley ER, Abraham D: Colony-stimulating factor-1 blockade by antisense oligonucleotides and small interfering RNAs suppresses growth of human mammary tumor xenografts in mice. Cancer Res 2004, 64: 5378–5384. 10.1158/0008-5472.CAN-04-0961CrossRefPubMed

76.

Forssell J, Oberg A, Henriksson ML, Stenling R, Jung A, Palmqvist R: High macrophage infiltration along the tumor front correlates with improved survival in colon cancer. Clin Cancer Res 2007, 13: 1472–1479. 10.1158/1078-0432.CCR-06-2073CrossRefPubMed

77.

Ma J, Liu L, Che G, Yu N, Dai F, You Z: The M1 form of tumor-associated macrophages in non-small cell lung cancer is positively associated with survival time. BMC Cancer 2010, 10: 112. 10.1186/1471-2407-10-112PubMedCentralCrossRefPubMed

78.

Kan-Mitchell J, Hengst JC, Kempf RA, Rothbart RK, Simons SM, Brooker AS, Kortes VL, Mitchell MS: Cytotoxic activity of human pulmonary alveolar macrophages. Cancer Res 1985, 45: 453–458.PubMed

79.

Mantovani A, Peri G, Polentarutti N, Bolis G, Mangioni C, Spreafico F: Effects on in vitro tumor growth of macrophages isolated from human ascitic ovarian tumors. Int J Cancer 1979, 23: 157–164. 10.1002/ijc.2910230204CrossRefPubMed

80.

Ino Y, Yamazaki-Itoh R, Shimada K, Iwasaki M, Kosuge T, Kanai Y, Hiraoka N: Immune cell infiltration as an indicator of the immune microenvironment of pancreatic cancer. Br J Cancer 2013, 108: 914–923. 10.1038/bjc.2013.32PubMedCentralCrossRefPubMed

81.

Herwig MC, Bergstrom C, Wells JR, Höller T, Grossniklaus HE: M2/M1 ratio of tumor associated macrophages and PPAR-gamma expression in uveal melanomas with class 1 and class 2 molecular profiles. Exp Eye Res 2013, 107: 52–58.PubMedCentralCrossRefPubMed

82.

Comito G, Giannoni E, Segura CP, Barcellos-de-Souza P, Raspollini MR, Baroni G, Lanciotti M, Serni S, Chiarugi P: Cancer-associated fibroblasts and M2-polarized macrophages synergize during prostate carcinoma progression. Oncogene 2013. Epub ahead of print, doi:10.1038/onc.2013.191

83.

Cui YL, Li HK, Zhou HY, Zhang T, Li Q: Correlations of tumor-associated macrophage subtypes with liver metastases of colorectal cancer. Asian Pac J Cancer Prev 2013, 14: 1003–1007. 10.7314/APJCP.2013.14.2.1003CrossRefPubMed

Title: A high M1/M2 ratio of tumor-associated macrophages is associated with extended survival in ovarian cancer patients
Authors: Meiying Zhang
Yifeng He
Xiangjun Sun
Qing Li
Wenjing Wang
Aimin Zhao
Wen Di
Publication date: 01-12-2014
Publisher: BioMed Central
Published in: Journal of Ovarian Research / Issue 1/2014
Electronic ISSN: 1757-2215
DOI: https://doi.org/10.1186/1757-2215-7-19

Keynote webinar | Spotlight on medication adherence

Springer Medicine

A high M1/M2 ratio of tumor-associated macrophages is associated with extended survival in ovarian cancer patients

Abstract

Background

Methods

Results

Conclusions

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2014

Changes in granulosa cells gene expression associated with growth, plateau and atretic phases in medium bovine follicles

Role of nerve growth factor and its TRKA receptor in normal ovarian and epithelial ovarian cancer angiogenesis

Does bariatric surgery improve ovarian stimulation characteristics, oocyte yield, or embryo quality?

Synchronous adrenal metastasis and an inferior vena cava tumor thrombus from an ovarian carcinoma

Effect of exercise intensity on weight changes and sexual hormones (androstenedione and free testosterone) in female rats with estradiol valerate-induced PCOS

Antibodies against Hsp60 and Hsp65 in the sera of women with ovarian cancer